JPH09502612A - ヒト悪性腫瘍のプリンヌクレオシドホスホリラーゼによる遺伝子治療法 - Google Patents
ヒト悪性腫瘍のプリンヌクレオシドホスホリラーゼによる遺伝子治療法Info
- Publication number
- JPH09502612A JPH09502612A JP7509251A JP50925195A JPH09502612A JP H09502612 A JPH09502612 A JP H09502612A JP 7509251 A JP7509251 A JP 7509251A JP 50925195 A JP50925195 A JP 50925195A JP H09502612 A JPH09502612 A JP H09502612A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- enzyme
- pnp
- gene
- purine analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a) プリンアナログ基質を切断して、細胞毒性プリンアナログをつくりだ す酵素を細胞に提供するステップと、 (b) 上記酵素によって切断された場合に、それら標的細胞を殺すのに十分 な量のプリンアナログ基質を上記細胞に提供するステップとで構成される標的と される哺乳動物細胞を殺す方法。 2.上記標的細胞が腫瘍細胞である請求項1の方法。 3.上記標的細胞がウィルスによる感染された細胞である請求項1の方法。 4.上記標的細胞がプリンアナログ基質を切断する酵素に加えて、治療用蛋白質 をつくりだすように加工される請求項1の方法。 5.上記酵素がバクテリア性PNPまたはヒドロラーゼである請求項1の方法。 6.上記酵素が修正された哺乳動物のPNPまたはヒドロラーゼである請求項1 の方法。 7.上記酵素が、その酵素をそれら細胞に向かわせることによって提供される請 求項1の方法。 8.上記酵素が、上記酵素を抗体に接種することによって上記細胞に向かわせる 請求項7の方法。 9.上記酵素がそれら細胞に提供された遺伝子によってコード表現される請求項 1の方法。 10.上記遺伝子が組織特異性プロモーター、または構成的 プロモーターに操作的に結合される請求項9の方法。 11.上記細胞に提供された遺伝子が大腸菌PNPをコード表現する請求項10の方 法。 12.大腸菌PNPをコード表現する上記遺伝子が、チロシナーゼ遺伝子プロモー ターに操作的に結合される請求項11の方法。 13.大腸菌PNPをコード表現する遺伝子がSV40初期プロモーター、モロニー マウスサルコーマウィルス長端末反復(long terminal repeat)、マウス乳腺腫 瘍ウィルス長端末反復およびサイトメガロウィルス初期プロモーターで構成され るグループから選択されるプロモーターに操作的に結合される請求項11の方法。 14.上記遺伝子がベクターに提供される請求項9による方法。 15.上記遺伝子が上記細胞に向かわせられる請求項9の方法。 16.上記遺伝子が、ポリマー性薄膜、ゲル、微小粒子およびリポソームなどの基 質分子に提供される請求項9による方法。 17.上記プリンアナログ基質が、9−(β−D−2−デオキシエリスロペントフ ラノシル)−6−メチルプリン、2−アミノ−6−クロロ−1−デアザプリンリ ボシド、7−リボシル−3−デアザグアイニン、アラビノフラノシル 2−フル オロアデニン、2−フルオロ−2′−デ オキシアデノシン、2−フルオロ−5′−デオキシアデノシン、2−クロロ−2 ′−デオキシ−アデノシン、5′−アミノ−5′−デオキシ−アデノシン、α− アデノシンで構成されるグループから選択される請求項1の方法。 18.上記標的細胞に酵素を与え、次に、その措置を必要としている患者に投与す る請求項1の方法。 19.上記酵素が、その酵素を含んでいるバクテリアを標的細胞に投与することに よって提供される請求項1の方法。 20.(a) プリンアナログ基質を切断し、細胞毒性のプリンアナログをつくりだ す酵素と、そして (b) 上記酵素によって切断された場合に、標的細胞を殺すのに効果的な量 の上記プリンアナログ基質とで構成される標的哺乳動物細胞を殺す組成物。 21.上記標的細胞が腫瘍細胞である請求項20による組成物。 22.上記標的細胞がウィルスによって感染された細胞である請求項20の組成物。 23.上記標的細胞が、プリンアナログ基質を切断する酵素に加えて、治療用蛋白 質をつくりだすように加工されている請求項20の組成物。 24.上記酵素がバクテリア性PNPまたはヒドロラーゼである請求項20の組成物 。 25.上記酵素が修正された哺乳動物PNPまたはヒドロラーゼである請求項20に よる組成物。 26.上記酵素が細胞に向かわせられる請求項20による組成 物。 27.上記酵素が抗体に接種される請求項26の組成物。 28.上記酵素が上記細胞に提供された遺伝子によってコード表現される請求項20 による組成物。 29.上記酵素をコード表現する遺伝子が組織特異性プロモーターまたは構成的プ ロモーターに操作的に結合される請求項28による組成物。 30.上記遺伝子が大腸菌PNPをコード表現する請求項29の組成物。 31.大腸菌PNPをコード表現する遺伝子がチロシナーゼ遺伝子プロモーターに 操作的に結合される請求項30の組成物。 32.大腸菌PNPをコード表現する上記遺伝子が、SV40初期プロモーター、モ ロニーマウスサルコーマウィルス長端末反復、マウス乳腺腫瘍ウィルス長端末反 復およびサイトメガロウィルス初期プロモーターで構成されるグループから選択 される請求項30の組成物。 33.上記遺伝子がベクターに提供される請求項28の組成物。 34.上記遺伝子がポリマー性薄膜、ゲル、微小粒子およびリポソームなどの基質 分子に提供される請求項28の組成物。 35.上記プリンアナログ基質が、9−(β−D−2−デオキシエリスロペントフ ラノシル)−6−メチルプリン、2−アミノ−6−クロロ−1−デアザプリン、 7−リボ シル−3−デアザグアミン、アラビノフラノシル 2−フルオロアデニン、2− フルオロ−2′−デオキシアデノシン、2−フルオロ−5′−デオキシアデノシ ン、2−クロロ−2′−デオキシ−アデノシン、5′−アミノ−5′−デオキシ −アデノシン、α−アデノシンで構成されるグループから選択される請求項20に よる組成物。 36.(a) プリンアナログ基質を切断して細胞毒性のあるプリンアナログをつく りだす酵素をコード表現する酵素または遺伝子を分離するステップと、 (b) 上記プリンアナログ基質が上記酵素によって切断された場合に、標的 細胞を殺すのに有効な量のプリンアナログ基質を選択するステップとで構成され る標的哺乳動物細胞を殺す組成物を製造する方法。 37.上記標的細胞が腫瘍細胞である請求項36の方法。 38.上記標的細胞がウィルスによる感染された細胞である請求項36の方法。 39.上記標的細胞がプリンアナログ基質を切断する酵素に加えて、治療用蛋白質 をつくりだすように加工される請求項36の方法。 40.上記酵素がバクテリア性PNPまたはヒドロラーゼである請求項36の方法。 41.上記酵素、または上記酵素をコード表現する遺伝子がバクテリア、菌類また はヒト寄生種から分離される請求項36の方法。 42.上記酵素または上記酵素をコード表現する遺伝子が大腸菌から分離される請 求項36の方法。 43.さらに上記酵素をコード表現する遺伝子を組織特異性プロモーターまたは構 成的プロモーターに操作的に結合するステップを含んでいる請求項42の方法。 44.上記遺伝子がチロシナーゼ遺伝子プロモーターに操作的に結合される大腸菌 PNPをコード表現する請求項43の方法。 45.上記遺伝子が、SC40初期プロモーター、モロニーマウスサルコーマウィル ス長端末反復、マウス乳腺腫瘍ウィルス長端末反復およびサイトメガロウィルス 初期プロモーターで構成されるグループから選択されるプロモーターに操作的に 結合されることを特徴とする請求項43の方法。 46.上記プリンアナログ基質が、9−(β−D−2−デオキシエリスロペントフ ラノシル)−6−メチルプリン、2−アミノ−6−クロロ−1−デアザプリンリ ボシド、7−リボシル−3−デアザグアイニン、アラビノフラノシル 2−フラ ノアデニン、2−フルオロ−2′−デオキシアデノシン、2−フルオロ−5′− デオキシアデノシン、2−クロロ−2′−デオキシ−アデノシン、5′−アミノ −5′−デオキシ−アデノシン、α−アデノシンで構成されるグループから選択 される請求項36の方法。 47.哺乳動物PNPによってプリンアナログをつくりだす 組成物の切断率を、非哺乳動物PNP、修正哺乳動物PNPまたは相当切断酵素 による切断率を比較するステップを含む、標的哺乳動物細胞を殺す方法において 有用なプロドラッグをスクリーニングする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US122,321 | 1993-09-14 | ||
US08/122,321 US5552311A (en) | 1993-09-14 | 1993-09-14 | Purine nucleoside phosphorylase gene therapy for human malignancy |
PCT/US1994/010130 WO1995007718A2 (en) | 1993-09-14 | 1994-09-14 | Purine nucleoside phosphorylase gene therapy for human malignancy |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502612A true JPH09502612A (ja) | 1997-03-18 |
JP3874420B2 JP3874420B2 (ja) | 2007-01-31 |
Family
ID=22402034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50925195A Expired - Fee Related JP3874420B2 (ja) | 1993-09-14 | 1994-09-14 | ヒト悪性腫瘍のプリンヌクレオシドホスホリラーゼによる遺伝子治療法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5552311A (ja) |
EP (1) | EP0715523B1 (ja) |
JP (1) | JP3874420B2 (ja) |
CA (1) | CA2171618C (ja) |
DE (1) | DE69431911T2 (ja) |
WO (1) | WO1995007718A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006199617A (ja) * | 2005-01-20 | 2006-08-03 | Institute Of Physical & Chemical Research | イミダゾピリジン誘導体 |
JP2012500224A (ja) * | 2008-08-15 | 2012-01-05 | ザ ユーエイビー リサーチ ファンデイション | ヌクレアーゼプロドラッグの酵素アクチベーターとしてのプリンヌクレオシドホスホリラーゼ |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6017896A (en) * | 1993-09-14 | 2000-01-25 | University Of Alabama Research Foundation And Southern Research Institute | Purine nucleoside phosphorylase gene therapy for human malignancy |
US6491905B1 (en) * | 1993-09-14 | 2002-12-10 | The Uab Research Foundation | Recombinant bacterial cells for delivery of PNP to tumor cells |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
CA2222574A1 (en) * | 1995-06-07 | 1996-12-19 | Yale University | Oral delivery of adeno-associated viral vectors |
KR100449181B1 (ko) * | 1995-06-15 | 2005-01-24 | 크루셀 홀란드 비.브이. | 유전자요법에사용할수있는사람의재조합아데노바이러스패키징시스템 |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
AUPN477695A0 (en) * | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
US6465484B1 (en) * | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
GB9721901D0 (en) | 1997-10-16 | 1997-12-17 | Univ Manchester | Particles |
US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
CA2421864A1 (en) * | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
DE60138403D1 (de) * | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
WO2003002746A2 (en) * | 2001-06-29 | 2003-01-09 | Novartis Ag | Perv screening method and use thereof |
US7037718B2 (en) | 2001-10-26 | 2006-05-02 | Cornell Research Foundation, Inc. | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
US7488598B2 (en) | 2001-10-26 | 2009-02-10 | Cornell Center For Technology Enterprise And Commercialization | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
WO2003049763A1 (en) | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition for the preservation of viruses |
AU2003211103A1 (en) * | 2002-02-13 | 2003-09-04 | Northeastern University | Intracellular delivery of therapeutic agents |
DK1497438T3 (da) * | 2002-04-25 | 2010-01-04 | Crucell Holland Bv | Midler og fremgangsmåder til fremstilling af adenovirusvektorer |
WO2004027029A2 (en) * | 2002-09-19 | 2004-04-01 | Ximerex, Inc. | Growth of foreign cells in fetal animals facilitated by conditional and selective destruction of native host cells |
US20070167353A1 (en) * | 2003-10-24 | 2007-07-19 | John Hilfinger | Prodrug composition |
US20050137141A1 (en) * | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
WO2008082440A2 (en) * | 2006-08-25 | 2008-07-10 | Emory University | Fluorescent nucleoside analogues |
DE102007008890A1 (de) | 2007-02-21 | 2008-09-04 | Universität Hamburg | Nukleinsäure, die für eine pflanzliche Adenosin-Nukleosidase kodiert |
US20110023152A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of cognition related genes in animals |
US20110023141A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved with parkinson's disease |
US20110023148A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of addiction-related genes in animals |
US20110016539A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of neurotransmission-related genes in animals |
US20110023151A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of abc transporters |
US20110023143A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of neurodevelopmental genes in animals |
US20110023139A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in cardiovascular disease |
US20110023156A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Feline genome editing with zinc finger nucleases |
US20110023150A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of genes associated with schizophrenia in animals |
US20110023140A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Rabbit genome editing with zinc finger nucleases |
US20110023149A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in tumor suppression in animals |
US20110016543A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genomic editing of genes involved in inflammation |
US20110023145A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in autism spectrum disorders |
US20110016540A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of genes associated with trinucleotide repeat expansion disorders in animals |
US20110030072A1 (en) * | 2008-12-04 | 2011-02-03 | Sigma-Aldrich Co. | Genome editing of immunodeficiency genes in animals |
US20110016541A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of sensory-related genes in animals |
US20110023153A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in alzheimer's disease |
US20110023154A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Silkworm genome editing with zinc finger nucleases |
US20110016546A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Porcine genome editing with zinc finger nucleases |
US20110023146A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in secretase-associated disorders |
US20110023158A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Bovine genome editing with zinc finger nucleases |
US20110023147A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of prion disorder-related genes in animals |
US20110023144A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in amyotrophyic lateral sclerosis disease |
AP3584A (en) | 2010-09-22 | 2016-02-09 | Alios Biopharma Inc | Substituted nucleotide analogs |
PL2797613T3 (pl) | 2011-10-27 | 2020-06-15 | Wellstat Ophthalmics Corporation | Wektory kodujące pręcikowy czynnik żywotności czopków |
WO2013096680A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6157845B2 (ja) * | 1979-04-17 | 1986-12-09 | Mitsubishi Chem Ind | |
JPS62129749A (ja) * | 1985-11-29 | 1987-06-12 | Toyota Motor Corp | 雨センサ |
US4743902A (en) * | 1977-12-09 | 1988-05-10 | Stiftelsen Institutet For Mikrovagsteknik Vid Tekniska Hogskolan | Measuring device for capacitive determination of the relative position of the two with respect to one another movable parts |
JP4094563B2 (ja) * | 2004-02-16 | 2008-06-04 | 株式会社エース電研 | 遊技機 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8907617D0 (en) * | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8919607D0 (en) * | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
-
1993
- 1993-09-14 US US08/122,321 patent/US5552311A/en not_active Expired - Lifetime
-
1994
- 1994-09-14 CA CA002171618A patent/CA2171618C/en not_active Expired - Lifetime
- 1994-09-14 WO PCT/US1994/010130 patent/WO1995007718A2/en active IP Right Grant
- 1994-09-14 JP JP50925195A patent/JP3874420B2/ja not_active Expired - Fee Related
- 1994-09-14 EP EP95902384A patent/EP0715523B1/en not_active Expired - Lifetime
- 1994-09-14 DE DE69431911T patent/DE69431911T2/de not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743902A (en) * | 1977-12-09 | 1988-05-10 | Stiftelsen Institutet For Mikrovagsteknik Vid Tekniska Hogskolan | Measuring device for capacitive determination of the relative position of the two with respect to one another movable parts |
JPS6157845B2 (ja) * | 1979-04-17 | 1986-12-09 | Mitsubishi Chem Ind | |
JPS62129749A (ja) * | 1985-11-29 | 1987-06-12 | Toyota Motor Corp | 雨センサ |
JP4094563B2 (ja) * | 2004-02-16 | 2008-06-04 | 株式会社エース電研 | 遊技機 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006199617A (ja) * | 2005-01-20 | 2006-08-03 | Institute Of Physical & Chemical Research | イミダゾピリジン誘導体 |
JP2012500224A (ja) * | 2008-08-15 | 2012-01-05 | ザ ユーエイビー リサーチ ファンデイション | ヌクレアーゼプロドラッグの酵素アクチベーターとしてのプリンヌクレオシドホスホリラーゼ |
Also Published As
Publication number | Publication date |
---|---|
WO1995007718A3 (en) | 1995-04-13 |
DE69431911T2 (de) | 2003-05-28 |
EP0715523A1 (en) | 1996-06-12 |
US5552311A (en) | 1996-09-03 |
EP0715523B1 (en) | 2002-12-18 |
WO1995007718A2 (en) | 1995-03-23 |
CA2171618C (en) | 2007-12-11 |
JP3874420B2 (ja) | 2007-01-31 |
DE69431911D1 (de) | 2003-01-30 |
CA2171618A1 (en) | 1995-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3874420B2 (ja) | ヒト悪性腫瘍のプリンヌクレオシドホスホリラーゼによる遺伝子治療法 | |
US6017896A (en) | Purine nucleoside phosphorylase gene therapy for human malignancy | |
US6958318B2 (en) | Recombinant bacterial cells for delivery of PNP to tumor cells | |
Danks et al. | Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy | |
US7037718B2 (en) | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | |
JPH08506239A (ja) | 標的細胞に対して特異的な、修飾された結合部分を有するウイルス | |
US20160022784A1 (en) | Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs | |
US7488598B2 (en) | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | |
Hong et al. | Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene | |
US7018834B2 (en) | Mutated herpes simplex virus type 1 thymidine kinases and uses thereof | |
US20090104154A1 (en) | Composition and method for killing of tumours | |
Curlee et al. | Tumor sensitization to purine analogs by E. coli PNP | |
PN et al. | An Overview on Enzyme Prodrug Therapy for Cancer. | |
Morin | Pharmaceuticai Sciences | |
Springer et al. | Patent property of suicide gene therapy involving prodrugs 1996-1999 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051216 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20051216 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060529 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060901 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061003 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061024 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101102 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121102 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |